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Introduction: Small-cell colon carcinoma is a very rare disease among colon neoplasms; it is difficult to achieve
long-term survival due to its aggressive tumor behavior. Here we report the long-term survival of a patient with
advanced small-cell colon carcinoma achieved by a combination of surgery and continuous chemotherapy.
Case presentation: A 67-year-old Japanese man underwent abdominal computed tomography in our institution
for follow up after gastrectomy, and abnormal thickness of the sigmoid colon wall was revealed. An endoscopy
demonstrated a 20mm Bormann 2 lesion with central ulceration located 20cm from the anal verge. A
sigmoidectomy was performed. Histologically, the tumor deeply invaded the tissue and extended beyond the
serosa, and was diagnosed as small-cell carcinoma. Cisplatin plus irinotecan was administered for adjuvant
chemotherapy. Nine months after surgery, a follow-up computed tomography showed an enlarged lymph node
behind the inferior vena cava and a 15×8mm nodule located at the ventral side of the cecum. Under consideration
of progressive disease, cisplatin plus irinotecan therapy was performed again using the same regimen. After nine
cycles of cisplatin plus irinotecan therapy, a follow-up gastric endoscopy demonstrated external tumor invasion to
the duodenum wall. Carboplatin plus etoposide therapy was selected as a third-line regimen. After six cycles of
carboplatin plus etoposide therapy, the recurrence sites were maintained in a stable condition, and the survival
time reached approximately 30 months after the initial surgery.
Conclusions: We report the long-term survival of a patient with advanced small-cell colon carcinoma. In the future,
the accumulation and analysis of rare cases that obtain a better survival time will contribute to clarifying
neuroendocrine carcinoma biology, and help to improve the prognosis.
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According to the classification of neuroendocrine tu-
mors by the World Health Organization (WHO), small-
cell colon carcinoma is categorized as a neuroendocrine
carcinoma (NEC), which has high malignancy [1]. A
NEC can occur anywhere in the gastrointestinal tract
but it is rarely found in the colon: NEC has an incidence
rate of only 0.6% of total colon malignancies [2]. Due to
aggressive tumor behavior, distant metastases in internal
organs or regional lymph nodes are often found at the
same time as detection of a tumor. In addition to these
facts, high recurrence rates contribute to poor survival,* Correspondence: computerbody@hotmail.com
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reproduction in any medium, provided the orwith a median survival of 10.5 months [2]. In patients
with a metastatic lesion at the time of the surgery, the
median survival time is only four months [3].
Here we report the long-term survival of a patient
with advanced small-cell colon cancer who received con-
tinuous chemotherapy.
Case presentation
A 67-year-old Japanese man underwent abdominal
computed tomography (CT) in our institution for fol-
low up after gastrectomy; the CT revealed abnormal
thickness of his sigmoid colon wall and further studies
were planned. Two years previously, he had undergone
a distal gastrectomy due to gastric cancer (moderately
differentiated adenocarcinoma), and received S-1 (tegafur-
gimeracil, 100mg) orally for 14 days followed by a seven-
day rest period as adjuvant therapy for two years. He alsotd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Macroscopic findings. A 15×20mm sub-mucosal tumor
with the appearance of a small central ulceration was observed in
the sigmoid colon.
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physical examination except for an upper abdominal mid-
line scar due to previous surgery, and his performance sta-
tus was grade 0. There were no abnormalities found on
laboratory tests.
A double contrast radiological examination with bar-
ium enema showed a protruding lesion with a smooth
surface at the distal end of the sigmoid colon, and the
lumen was narrowed for approximately 2cm. An endos-
copy demonstrated a 20mm Bormann 2 lesion with cen-
tral ulceration located 20cm from the anal verge
(Figure 1). No metastatic sites in other internal organs
were confirmed by CT.
Multiple biopsies from the main site showed group V
malignant cells that were positive for chromogranin A,
synaptophysin, and CD56, and proved to be a NEC.
Under a diagnosis of NEC, a sigmoidectomy was
performed. During the operation, three small hard white
nodes were found at the mesenteric and pelvic cavity.
The main tumor was located at 20cm on the oral side of
the peritoneal reflection, and dissected by three enlarged
paracolic lymph nodes.
Macroscopically, a 15×20mm sub-mucosal tumor with
the appearance of a small central ulceration was ob-
served in the sigmoid colon (Figure 2).
Microscopically, the tumor deeply invaded the tissue
and extended beyond the serosa. On hematoxylin and
eosin staining, the tumor had high cellularity with ap-
pearance of hyperchromatic nuclei with irregular sheets,
rosette arrangements, and alveolar structures (Figure 3).
Immunohistochemical staining for chromogranin A,
synaptophysin, and CD56 were also positive, which indi-
cates an endocrine function (Figures 4 and 5). Several
ductal structures were occupied by mucinous fluid andFigure 1 Endoscopic findings. An endoscopy demonstrated a
20mm Bormann 2 lesion with a central ulceration located 20cm
from the anal verge.positivity for periodic acid-Schiff (PAS), PAS-diastase
(d-PAS), and Alcian blue was observed on the mucosal
surface, suggesting the adenocarcinoma was included
within the tumor. The nodules in the mesenteric and
paracolic lymph nodes were also pathologically diag-
nosed as metastases. Finally, the tumor was diagnosed
as a NEC (small-cell carcinoma).
Adjuvant chemotherapy was planned based on a regimen
for small-cell lung carcinoma. Cisplatin plus irinotecan
(cisplatin plus irinotecan therapy, cisplatin 60mg/m2 day 1
and irinotecan 60mg/m2 days 1, 8, and 15) were adminis-
tered. Only a grade 2 side effect of transaminitis was ob-
served during chemotherapy, and the patient recovered
conservatively from this side effect. After finishing five
cycles of chemotherapy, an evaluation CT showed no find-
ings of recurrence. After cisplatin plus irinotecan therapy
was finished, tegafur-uracil (UFT; 400mg) and leucovorin
(UZEL, 75mg) were administered orally for 28 daysFigure 3 Pathological appearance of small-cell colon carcinoma
on hematoxylin and eosin staining (original magnification
×100).
Figure 4 Synaptophysin was positive on immunohistochemical
staining (original magnification ×100).
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inferior vena cava and a 15×8mm nodule located at the
ventral side of the cecum, which raised a suspicion of mes-
enteric dissemination. Under consideration of progressive
disease, cisplatin plus irinotecan therapy was performed
again using the same regimen. After nine cycles of cis-
platin plus irinotecan therapy, a follow-up gastric en-
doscopy demonstrated external tumor invasion to the
anterior duodenum wall due to growing peritoneal dis-
semination. It seemed that the tumor had acquired a re-
sistance to cisplatin plus irinotecan therapy, and therefore
carboplatin plus etoposide therapy, carboplatin plus
etoposide therapy carboplatin 390mg day 1 + etoposide
96mg, 80% dose, days 1, 2, 3 were selected as a third-line
regimen. After six cycles of carboplatin plus etoposide
therapy, the peritoneal dissemination sites had not ex-
panded on CT findings, and the tumor invasion on the an-
terior duodenum wall had partially receded on endoscopicFigure 5 Chromogranin A was positive on immunohistochemical
staining (original magnification ×100).findings. At the present moment, the survival time has
reached approximately 30 months after the initial surgery.
Discussion
According to the 2010 WHO classification of neuroen-
docrine neoplasia (NET), NET was categorized into
grade 1 and grade 2 based on the malignant potential of
metastasis, and tumors with high malignancy were di-
vided into NEC or mixed adenoendocrine carcinoma,
which includes an element of adenocarcinoma of more
than 30% [1]. The present case was pathologically diag-
nosed as a small-cell carcinoma mixed with poor to
moderate adenocarcinoma elements of less than 30%,
and was categorized as NEC based on WHO classifica-
tions. When applying the present WHO classification,
special attention should be paid because previously well
or poorly differentiated endocrine carcinomas are re-
defined separately as NET grade 2 and NEC.
A definitive diagnosis was made histopathologically, and
immunohistochemical staining greatly helps in diagnosis
[4]. Saclarides et al. reported that more than a few cases
initially diagnosed as carcinoid were changed to NEC after
histopathological analysis [3]. In the present case, diagnosis
was made preoperatively based on the immunohistochemi-
cal staining of chromogranin A, synaptophysin, and CD56.
An endoscopic biopsy diagnosis is occasionally changed
from well to moderately differentiated colon adenocarcin-
oma to NEC by pathological evaluations after surgery [3].
When any specific structures of NEC are histologically
found, routine immunohistochemical staining contributes
to appropriate diagnosis and continuous early treatment.
Chemotherapy for NEC is often performed based on
the regimen for small-cell lung carcinoma. The latest
guidelines for small-cell lung carcinoma from the Na-
tional Comprehensive Cancer Network (NCCN) recom-
mend etoposide plus platinum agents such as cisplatin
or carboplatin for limited stage, and adding irinotecan
instead of etoposide for extensive stage [5]. The present
case initially received cisplatin plus irinotecan therapy,
and secondly carboplatin plus etoposide therapy was se-
lected because the tumor acquired resistance to cisplatin
plus irinotecan therapy. In the present case, which was
considered to have a high recurrence risk, UFT and
UZEL were selected for maintenance and carboplatin
plus etoposide therapy after the first cisplatin plus
irinotecan therapy was administered based on a colon
cancer regimen. Although the disease-free interval from
the first cisplatin plus irinotecan therapy to recurrence
was approximately four months, cisplatin plus irinotecan
therapy was selected again. In the NCCN guidelines for
small-cell lung cancer, when a recurrence is observed
less than six months after finishing chemotherapy, a dif-
ferent treatment regimen is recommended [5]. It might
have been better to change from cisplatin plus irinotecan
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of recurrence because the tumor had already shown re-
sistance to cisplatin plus irinotecan therapy.
It is very rare for patients with small-cell colon carcin-
oma to survive for approximately 30 months after being
diagnosed with stage IV disease and peritoneal dissemi-
nations. Some reports have shown long-term survival
despite an advanced stage by combination of operation
and effective chemotherapy [6,7]. Unfortunately, patient
characteristics associated with positive results from
chemotherapy and favorable outcomes are still unknown
because so few cases achieve long-term survival. A re-
cent clinical trial showed the efficacy of amrubicin, an
anthracycline agent with potent topoisomerase II inhib-
ition activity, in improving survival time as second-line
treatment for patients with small-cell lung cancer [8].
Although the number of cases was limited, Asayama
et al. also reported the efficacy of amrubicin as first-line
treatment for five cases of gastrointestinal endocrine car-
cinoma [9]. Earlier reports suggested that a certain per-
centage of patients with small-cell colon carcinoma had
sensitivity for chemotherapy and achieved a better prog-
nosis [6,7].
In general, small-cell colon carcinoma has a high risk
for recurrence and the follow-up method is important.
Because recurrence sites are found in various organs,
such as lymph nodes, liver, lung, and brain, less invasive
whole body screening is needed. A recent study showed
the effectiveness of somatostatin receptor scintigraphy
on diagnosis and follow up by using an 111indium
pentetreotide that specifically associated with the som-
atostatin receptor in NEC [10]. However, the superiority
of CT, magnetic resonance imaging, and somatostatin
receptor scintigraphy is still controversial, and regular
whole body screening and reassessment of chemothera-
peutic effect is essential.
Conclusion
In this patient, long-term survival was achieved with a
combination of surgery and chemotherapy, even though
the cancer was at an advanced stage. The ideal strategy
for advanced small-cell colon carcinoma has not yet
been established. However, if it is determined before the
operation that the tumor is advanced, then tumor resec-
tion should be performed, and selecting a chemotherapy
regimen based on established guidelines will contribute
to a better prognosis.
In the future, the accumulation and analysis of rare
cases that obtain a better survival time will contribute to
clarify NEC biology, and help to improve the prognosis.
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